ILMN up +0.96% percent Today $ILMN High is at 182.
Post# of 63
Posted On: 11/17/2014 11:00:20 AM
ILMN up +0.96% percent Today $ILMN High is at 182.24 and the Low 176.93 with current volume of 324,965.
Recent News posted below.
Illumina Inc ILMN other info.
http://investorshangout.com/Illumina-ILMN-54443/
ILMN Illumina Inc Recent Headline News
Strength Seen in Geron (GERN): Stock Surges 19.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 34 mins ago
Geron (GERN) was a big mover last session, with shares surging over 19% on the day.
BIIB: 306.66 (+1.23), GERN: 3.02 (+0.26), ILMN: 182.52 (+2.02), AFFX: 9.41 (-0.30)
Sequenta Enters Agreement with Illumina on In Vitro Diagnostic Kit for Sequencing-Based Minimal Residual Disease Testing
Business Wire - 1 hr 58 mins ago
Sequenta, Inc., a biotechnology company developing clinical diagnostics based on immune cell receptor genes, today announced that the company has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN). The purpose of the agreement is to commercialize an in vitro diagnostic (IVD) kit that will enable clinical laboratories to utilize Sequenta's next-generation sequencing (NGS)-based minimal residual disease (MRD) detection and quantification technology.
ILMN: 182.52 (+2.02)
Medical Stocks Tumble But Most Of IBD 50 Trading Well
at Investor's Business Daily - Fri Nov 14, 5:47PM CST
A few medical leading stocks have slid, but otherwise the IBD 50 remained in good shape last week. Illumina (ILMN) and Akorn (AKRX) have fallen below their buy points, while Alexion Pharmaceuticals (ALXN) and Celgene (CELG) exhibited some weakness of...
AKRX: 38.68 (+0.47), ALXN: 189.55 (+0.79), FFIV: 127.49 (-1.39), ILMN: 182.52 (+2.02), SPR: 41.08 (-0.12), AAPL: 114.53 (+0.35), ATHM: 43.35 (-1.23), BITA: 89.16 (-2.75), CELG: 104.96 (+0.91)
Stock Market Treads Water; Earnings Drive BitAuto
at Investor's Business Daily - Fri Nov 14, 3:21PM CST
Stocks struggled for direction for most of the day Friday amid upbeat data on retail sales and consumer sentiment. But the main indexes ultimately ended mildly higher. The Nasdaq edged up 0.2%, thanks to strength in software and solar issues. But...
NTES: 100.53 (-0.11), ILMN: 182.52 (+2.02), BITA: 89.16 (-2.75), CELG: 104.96 (+0.91)
Stocks Mixed; Amazon Jumps On Book Deal
at Investor's Business Daily - Fri Nov 14, 12:32PM CST
Stocks were mixed, but gained a small amount of ground in afternoon trading Friday. A better-than-expected retail sales report lifted Wall Street spirits in the stock market today. The Nasdaq gained 0.1%; the Dow Jones industrial average dropped...
BIIB: 306.66 (+1.23), AMZN: 320.63 (-7.19), HAL: 51.05 (-4.03), ILMN: 182.52 (+2.02), BITA: 89.16 (-2.75), BHI: 67.42 (+7.53), CELG: 104.96 (+0.91)
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:40PM CST
Sarepta (SRPT) announced that it has enrolled the first patient in an open label study on eteplirsen in non-ambulant Duchenne muscular dystrophy patients.
RNA: 11.31 (+0.04), SRPT: 15.18 (-0.14), ILMN: 182.52 (+2.02), CELG: 104.96 (+0.91)
Illumina Falls 1.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 13, 4:25PM CST
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $183.84 to a high of $191.62. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $186.11 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 182.52 (+2.02)
Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:00PM CST
Ligand Pharma (LGND) announced the submission of a Marketing Authorisation Application to the European Medicines Agency by its partner GlaxoSmithKline for Revolade.
LGND: 57.63 (-0.16), ILMN: 182.52 (+2.02), GSK: 45.87 (+0.13), CELG: 104.96 (+0.91)
Qiagen Partners with Novartis for Companion Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 1:20PM CST
Qiagen N.V. (QGEN) has signed a master collaboration agreement with Novartis.
ICUI: 86.54 (+0.83), ILMN: 182.52 (+2.02), QGEN: 23.56 (unch), NVS: 94.49 (+0.54)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 306.66 (+1.23), ALNY: 89.61 (-0.51), ILMN: 182.52 (+2.02), AMAG: 34.80 (+0.80)
Brand Timbre Develops Audio-Identity Platform for World's Largest Genomics Company
Marketwired - Wed Nov 12, 6:00AM CST
Brand Timbre LLC, a strategic sonic branding agency, has completed work on the first stage of a comprehensive audio-branding initiative for Illumina Inc. Illumina is an industry-leading life-sciences company that designs, develops and manufactures DNA and genetics sequencing machines used in labs throughout the world. Brand Timbre's multi-phase project includes an audio-branding strategy, an audio-identity profile that defines Illumina's sound, an audio logo, and product-sonification (sound design) assets for Illumina's sequencing instruments.
ILMN: 182.52 (+2.02)
Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - Tue Nov 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ACHN, CLDX, KNDI, ILMN and AMD.
KNDI: 14.21 (+0.48), AMD: 2.63 (+0.02), ACHN: 13.75 (-0.22), CLDX: 17.83 (+3.67), ILMN: 182.52 (+2.02)
Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:44AM CST
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares surge a little over 27% on the day
HSKA: 15.36 (-0.18), ACHN: 13.75 (-0.22), ILMN: 182.52 (+2.02), AFFX: 9.41 (-0.30)
Global Preimplantation Genetic Diagnosis (PGD for Chromosomal Aberrations, Aneuploidy Screening, Gender Selection, Single Gene Disorders, HLA Typing and X-linked Diseases) Market - Trends and Forecast to 2020
M2 - Tue Nov 11, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/sm76mf/preimplantation) has announced the addition of the "Preimplantation Genetic Diagnosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Since the last two decades, preimplantation genetic diagnosis (PGD) has been used to detect chromosomal aneuploidy in low prognosis patients who undergo in-vitro fertilization (IVF). PGD is now being used to detect a broader range of indications due to advancements in the medical technology. These indications include chromosomal aberrations, genetic abnormalities, gender selection, HLA typing, X-linked diseases and single gene diseases. Demand for PGD is continuously increasing in patients who undergo IVF in the hope that it would improve the probability of live birth and reduce the chances of disabilities and genetic disorders in the offspring. This report provides in-depth analysis of the preimplantation genetic diagnosis market and its test types across various regions. Stakeholders in the report include diagnostic laboratories that provide PGD services, companies involved in the production of diagnosis kits and sequencers for PGD, and prospective market players planning to enter the market. The report comprises executive summary, which offers a market snapshot that covers the overall information about various types of tests in the PGD market. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Preimplantation Genetic Diagnosis Market Overview Chapter 4 Global Preimplantation Genetic Diagnosis Market, by Test Type Chapter 5 Preimplantation Genetic Diagnosis Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles Companies Mentioned: - Genea Ltd. - Genesis Genetics - Illumina, Inc. - Laboratory Corporation of America Holdings (LabCorp) - Natera, Inc. - PerkinElmer, Inc. - Quest Diagnostics, Inc. - Reproductive Genetics Institute - Reprogenetics LLC For more information visit http://www.researchandmarkets.com/research/sm...plantation
DGX: 62.31 (-0.10), LH: 98.92 (+0.08), ILMN: 182.52 (+2.02), PKI: 43.38 (-0.27)
Winning Stock Picking Ideas from Last Week's Jobs Report - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Nov 11, 3:18AM CST
Winning Stock Picking Ideas from Last Week's Jobs Report - Screen of the Week
CST: 41.84 (+0.34), JACK: 71.04 (-0.71), IHS: 131.51 (-0.10), ILMN: 182.52 (+2.02)
Big Cap 20 Stuffed With Medical Names
at Investor's Business Daily - Mon Nov 10, 6:34PM CST
Nine of the Big Cap 20 names this week are in medical-related fields, revealing that the leadership among these names over the past few years has continued despite October's correction, which whittled more than 10% off the Nasdaq. Alexion...
ABC: 88.87 (+0.04), VRX: 135.94 (+1.73), ALXN: 189.55 (+0.79), AMGN: 159.20 (+1.52), MYL: 55.53 (+1.48), ILMN: 182.52 (+2.02), CELG: 104.96 (+0.91)
A/D Rating Helps Spot What The Pros Are Buying
at Investor's Business Daily - Thu Nov 06, 5:41PM CST
If you're prepping a small patch of land, a shovel and a hoe from Home Depot (HD) will suffice. But if you have acres to dig up, then you'll need industrial-size earth-moving equipment. In the stock market, it takes big money from professional...
BCC: 36.00 (-1.03), HD: 98.88 (+0.64), AKRX: 38.68 (+0.47), ILMN: 182.52 (+2.02)
'Mad Money' Lightning Round: Pull the Trigger on Baxter
at The Street - Thu Nov 06, 5:00AM CST
Cramer likes Illumina but isn't a big fan of GEO Group or AK Steel Holdings.
RIG: 25.77 (-0.28), GEO: 39.63 (-0.29), TMO: 118.16 (-0.59), ESV: 38.64 (-0.14), NUE: 53.84 (-0.07), BAX: 71.56 (-0.19), ILMN: 182.52 (+2.02), AKS: 6.47 (-0.07), OXY: 86.03 (-0.63)
Recent News posted below.
Illumina Inc ILMN other info.
http://investorshangout.com/Illumina-ILMN-54443/
ILMN Illumina Inc Recent Headline News
Strength Seen in Geron (GERN): Stock Surges 19.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 34 mins ago
Geron (GERN) was a big mover last session, with shares surging over 19% on the day.
BIIB: 306.66 (+1.23), GERN: 3.02 (+0.26), ILMN: 182.52 (+2.02), AFFX: 9.41 (-0.30)
Sequenta Enters Agreement with Illumina on In Vitro Diagnostic Kit for Sequencing-Based Minimal Residual Disease Testing
Business Wire - 1 hr 58 mins ago
Sequenta, Inc., a biotechnology company developing clinical diagnostics based on immune cell receptor genes, today announced that the company has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN). The purpose of the agreement is to commercialize an in vitro diagnostic (IVD) kit that will enable clinical laboratories to utilize Sequenta's next-generation sequencing (NGS)-based minimal residual disease (MRD) detection and quantification technology.
ILMN: 182.52 (+2.02)
Medical Stocks Tumble But Most Of IBD 50 Trading Well
at Investor's Business Daily - Fri Nov 14, 5:47PM CST
A few medical leading stocks have slid, but otherwise the IBD 50 remained in good shape last week. Illumina (ILMN) and Akorn (AKRX) have fallen below their buy points, while Alexion Pharmaceuticals (ALXN) and Celgene (CELG) exhibited some weakness of...
AKRX: 38.68 (+0.47), ALXN: 189.55 (+0.79), FFIV: 127.49 (-1.39), ILMN: 182.52 (+2.02), SPR: 41.08 (-0.12), AAPL: 114.53 (+0.35), ATHM: 43.35 (-1.23), BITA: 89.16 (-2.75), CELG: 104.96 (+0.91)
Stock Market Treads Water; Earnings Drive BitAuto
at Investor's Business Daily - Fri Nov 14, 3:21PM CST
Stocks struggled for direction for most of the day Friday amid upbeat data on retail sales and consumer sentiment. But the main indexes ultimately ended mildly higher. The Nasdaq edged up 0.2%, thanks to strength in software and solar issues. But...
NTES: 100.53 (-0.11), ILMN: 182.52 (+2.02), BITA: 89.16 (-2.75), CELG: 104.96 (+0.91)
Stocks Mixed; Amazon Jumps On Book Deal
at Investor's Business Daily - Fri Nov 14, 12:32PM CST
Stocks were mixed, but gained a small amount of ground in afternoon trading Friday. A better-than-expected retail sales report lifted Wall Street spirits in the stock market today. The Nasdaq gained 0.1%; the Dow Jones industrial average dropped...
BIIB: 306.66 (+1.23), AMZN: 320.63 (-7.19), HAL: 51.05 (-4.03), ILMN: 182.52 (+2.02), BITA: 89.16 (-2.75), BHI: 67.42 (+7.53), CELG: 104.96 (+0.91)
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:40PM CST
Sarepta (SRPT) announced that it has enrolled the first patient in an open label study on eteplirsen in non-ambulant Duchenne muscular dystrophy patients.
RNA: 11.31 (+0.04), SRPT: 15.18 (-0.14), ILMN: 182.52 (+2.02), CELG: 104.96 (+0.91)
Illumina Falls 1.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 13, 4:25PM CST
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $183.84 to a high of $191.62. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $186.11 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 182.52 (+2.02)
Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:00PM CST
Ligand Pharma (LGND) announced the submission of a Marketing Authorisation Application to the European Medicines Agency by its partner GlaxoSmithKline for Revolade.
LGND: 57.63 (-0.16), ILMN: 182.52 (+2.02), GSK: 45.87 (+0.13), CELG: 104.96 (+0.91)
Qiagen Partners with Novartis for Companion Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 1:20PM CST
Qiagen N.V. (QGEN) has signed a master collaboration agreement with Novartis.
ICUI: 86.54 (+0.83), ILMN: 182.52 (+2.02), QGEN: 23.56 (unch), NVS: 94.49 (+0.54)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 306.66 (+1.23), ALNY: 89.61 (-0.51), ILMN: 182.52 (+2.02), AMAG: 34.80 (+0.80)
Brand Timbre Develops Audio-Identity Platform for World's Largest Genomics Company
Marketwired - Wed Nov 12, 6:00AM CST
Brand Timbre LLC, a strategic sonic branding agency, has completed work on the first stage of a comprehensive audio-branding initiative for Illumina Inc. Illumina is an industry-leading life-sciences company that designs, develops and manufactures DNA and genetics sequencing machines used in labs throughout the world. Brand Timbre's multi-phase project includes an audio-branding strategy, an audio-identity profile that defines Illumina's sound, an audio logo, and product-sonification (sound design) assets for Illumina's sequencing instruments.
ILMN: 182.52 (+2.02)
Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - Tue Nov 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ACHN, CLDX, KNDI, ILMN and AMD.
KNDI: 14.21 (+0.48), AMD: 2.63 (+0.02), ACHN: 13.75 (-0.22), CLDX: 17.83 (+3.67), ILMN: 182.52 (+2.02)
Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:44AM CST
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares surge a little over 27% on the day
HSKA: 15.36 (-0.18), ACHN: 13.75 (-0.22), ILMN: 182.52 (+2.02), AFFX: 9.41 (-0.30)
Global Preimplantation Genetic Diagnosis (PGD for Chromosomal Aberrations, Aneuploidy Screening, Gender Selection, Single Gene Disorders, HLA Typing and X-linked Diseases) Market - Trends and Forecast to 2020
M2 - Tue Nov 11, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/sm76mf/preimplantation) has announced the addition of the "Preimplantation Genetic Diagnosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Since the last two decades, preimplantation genetic diagnosis (PGD) has been used to detect chromosomal aneuploidy in low prognosis patients who undergo in-vitro fertilization (IVF). PGD is now being used to detect a broader range of indications due to advancements in the medical technology. These indications include chromosomal aberrations, genetic abnormalities, gender selection, HLA typing, X-linked diseases and single gene diseases. Demand for PGD is continuously increasing in patients who undergo IVF in the hope that it would improve the probability of live birth and reduce the chances of disabilities and genetic disorders in the offspring. This report provides in-depth analysis of the preimplantation genetic diagnosis market and its test types across various regions. Stakeholders in the report include diagnostic laboratories that provide PGD services, companies involved in the production of diagnosis kits and sequencers for PGD, and prospective market players planning to enter the market. The report comprises executive summary, which offers a market snapshot that covers the overall information about various types of tests in the PGD market. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Preimplantation Genetic Diagnosis Market Overview Chapter 4 Global Preimplantation Genetic Diagnosis Market, by Test Type Chapter 5 Preimplantation Genetic Diagnosis Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles Companies Mentioned: - Genea Ltd. - Genesis Genetics - Illumina, Inc. - Laboratory Corporation of America Holdings (LabCorp) - Natera, Inc. - PerkinElmer, Inc. - Quest Diagnostics, Inc. - Reproductive Genetics Institute - Reprogenetics LLC For more information visit http://www.researchandmarkets.com/research/sm...plantation
DGX: 62.31 (-0.10), LH: 98.92 (+0.08), ILMN: 182.52 (+2.02), PKI: 43.38 (-0.27)
Winning Stock Picking Ideas from Last Week's Jobs Report - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Nov 11, 3:18AM CST
Winning Stock Picking Ideas from Last Week's Jobs Report - Screen of the Week
CST: 41.84 (+0.34), JACK: 71.04 (-0.71), IHS: 131.51 (-0.10), ILMN: 182.52 (+2.02)
Big Cap 20 Stuffed With Medical Names
at Investor's Business Daily - Mon Nov 10, 6:34PM CST
Nine of the Big Cap 20 names this week are in medical-related fields, revealing that the leadership among these names over the past few years has continued despite October's correction, which whittled more than 10% off the Nasdaq. Alexion...
ABC: 88.87 (+0.04), VRX: 135.94 (+1.73), ALXN: 189.55 (+0.79), AMGN: 159.20 (+1.52), MYL: 55.53 (+1.48), ILMN: 182.52 (+2.02), CELG: 104.96 (+0.91)
A/D Rating Helps Spot What The Pros Are Buying
at Investor's Business Daily - Thu Nov 06, 5:41PM CST
If you're prepping a small patch of land, a shovel and a hoe from Home Depot (HD) will suffice. But if you have acres to dig up, then you'll need industrial-size earth-moving equipment. In the stock market, it takes big money from professional...
BCC: 36.00 (-1.03), HD: 98.88 (+0.64), AKRX: 38.68 (+0.47), ILMN: 182.52 (+2.02)
'Mad Money' Lightning Round: Pull the Trigger on Baxter
at The Street - Thu Nov 06, 5:00AM CST
Cramer likes Illumina but isn't a big fan of GEO Group or AK Steel Holdings.
RIG: 25.77 (-0.28), GEO: 39.63 (-0.29), TMO: 118.16 (-0.59), ESV: 38.64 (-0.14), NUE: 53.84 (-0.07), BAX: 71.56 (-0.19), ILMN: 182.52 (+2.02), AKS: 6.47 (-0.07), OXY: 86.03 (-0.63)
(0)
(0)Illumina Inc. (ILMN) Stock Research Links
Scroll down for more posts ▼